Development of anemia in WT, C3−/−, and FcRγ−/− B6 mice injected with IgM, IgA, and IgG2a anti-RBC mAb
| mAb . | Dose . | WT* . | C3−/−* . | FcRγ−/−* . |
|---|---|---|---|---|
| 34-3C IgM | 25 μg | 30.1 ± 2.8 | 32.6 ± 1.5 | ND |
| 100 μg | 21.1 ± 5.8 | 22.4 ± 3.6 | ND | |
| 4C8 IgM | 100 μg | 24.9 ± 2.8 | 24.9 ± 3.1 | ND |
| 1E10 IgM | 100 μg | 19.8 ± 2.0 | 20.5 ± 0.5 | ND |
| 34-3C IgA | 100 μg | 25.4 ± 1.4 | 25.9 ± 3.7 | 24.7 ± 1.2 |
| 34-3C IgG2a | 100 μg | 20.4 ± 2.2† | 29.0 ± 3.2† | 37.1 ± 0.5† |
| mAb . | Dose . | WT* . | C3−/−* . | FcRγ−/−* . |
|---|---|---|---|---|
| 34-3C IgM | 25 μg | 30.1 ± 2.8 | 32.6 ± 1.5 | ND |
| 100 μg | 21.1 ± 5.8 | 22.4 ± 3.6 | ND | |
| 4C8 IgM | 100 μg | 24.9 ± 2.8 | 24.9 ± 3.1 | ND |
| 1E10 IgM | 100 μg | 19.8 ± 2.0 | 20.5 ± 0.5 | ND |
| 34-3C IgA | 100 μg | 25.4 ± 1.4 | 25.9 ± 3.7 | 24.7 ± 1.2 |
| 34-3C IgG2a | 100 μg | 20.4 ± 2.2† | 29.0 ± 3.2† | 37.1 ± 0.5† |
Ht values (means of 3 to 5 mice ± SD) 2 days after an intraperitoneal injection of IgM or IgA anti-RBC mAb or 4 days after injection of IgG2a anti-RBC mAb in WT, C3−/− or FcRγ−/− B6 mice. Ht values before injection of anti-RBC mAb in WT, C3−/− and FCRγ−/− mice were 44% to 48%.
Differences in Ht values among WT, C3−/−, and FcRγ−/− mice injected with 100 μg of 34-3C IgG2a mAb were significant (P < .05). ND indicates not determined.